

CRISPR-Cas9 Gene Therapy Effects on Inherited Eye Disorders

Chloe E. Pisack^{1*}, Krishna S. Patel^{1*}, and Tyler S. Batista-Nieto^{1*}

¹Geisinger College of Health Sciences, Scranton, PA 18509

*Master of Biomedical Sciences Program

Correspondence: cepisack1@som.geisinger.edu

Abstract

Stargardt's disease (STGD1), retinitis pigmentosa (RP), and Leber's congenital amaurosis (LCA) inherited eye conditions are among the main causes of blindness and visual impairment. The primary cause of these diseases, which lead to gradual vision loss, are genetic mutations affecting retinal cells. Gene-editing technologies, especially the CRISPR-Cas9 system, are emerging as promising ways to correct harmful genetic mutations. This review focuses on how effectively CRISPR-Cas9 can be used to treat certain inherited eye conditions. In experiments with patient-derived human induced pluripotent stem cells (hiPSCs), researchers were able to fix STGD1 mutations in the *ABCA4* gene using CRISPR-Cas9. The corrected cells retained their ability to differentiate into different cell types and showed minimal off-target effects. This suggests the approach could offer a safe and precise way of treating these conditions. In RP, CRISPR-Cas9 was used to target the *RPGR* gene in mice models, successfully preserving the shape and function of the photoreceptor cells. The CEP290 mutation in *LCA10* was corrected in human patients using the CRISPR-Cas9 based EDIT-101 in the BRILLIANCE clinical trial, which demonstrated a notable improvement in visual outcomes with minimal adverse effects. Even though the results so far are promising, challenges remain, including long-term safety, the administration of these treatments, and the risk of unintended effects. This review emphasizes the need for further research and clinical trials to improve these therapies. It also highlights the exciting potential of CRISPR-Cas9 as a curative treatment for inherited retinal disorders.

Introduction

The human eye is a very complex organ consisting of 3 major tissues: cornea, lens, and retina (1). Damage to any of these tissues can lead to visual impairments. Retinal disease or damage to the retina is the

primary cause of visual impairments (2). Stargardt's disease, retinitis pigmentosa, and Leber's congenital amaurosis are inherited eye disorders caused by damage to the retina or macula (3). Stargardt's disease is a macular dystrophy since the macula and cones are degenerated. Retinitis pigmentosa and Leber's congenital amaurosis are retinal dystrophies since the rods are affected more than the cones. Regardless of the dystrophy, there is progressive vision loss in all 3 disorders (3).

Clustered regularly interspaced palindromic repeats (CRISPR)-Cas9 is a gene editing tool that functions to correct errors in the genome (4). CRISPR-Cas9 turns the genes on or off to fix the mutation. CRISPR-Cas9 can correct a disease mutation, thus curing the genetic disorders of the mice. The 2 main components of CRISPR-Cas9 are guide RNA and Cas9. The guide RNA matches the sequence of the target gene, and Cas9 is an endonuclease that makes a double-stranded DNA break at the specific location on the genome (4). After the cut has been made, the cell's natural DNA repair mechanisms, homology-directed repair (HDR), and non-homologous end-joining (NHEJ) are recruited to repair the double-stranded break, which allows gene editing (5).

Therapeutic gene editing has advanced greatly within the last decade (6). However, gene editing and gene therapy are in their early stages of development. This focused review examines the advancement of gene editing and gene therapy in Stargardt's disease, retinitis pigmentosa, and Leber's congenital amaurosis.

Stargardt's Disease

Stargardt's disease (STGD1), also known as juvenile macular dystrophy, is an inherited autosomal recessive eye disorder (7). The disease causes vision loss and retinal degeneration in adults and children (7). Early onset of STGD1 is between 1 to 10 years of age (8). The range of late-onset STGD1 is 45 to 72 years of

age (9). The prevalence of the disease is 1 in 8,000 to 10,000 individuals (10). STGD1 causes retinal degeneration and vision loss (7). Such eye impairments are caused by a biallelic mutation on the *ABCA4* gene (11). The *ABCA4* gene plays a vital role in recycling retinoid byproducts (12). However, a mutation in the *ABCA4* gene can prevent the transportation of byproducts, thus leading to toxic buildup in the retina, which causes visual impairments (13).

Human induced pluripotent stem cells (hiPSCs) are stem cells that can differentiate into any cell type, enabling them to model any disease or drug screening (14). The use of hiPSCs is relevant to studying eye-related diseases since access to brain cells is challenging (15). However, with the use of hiPSCs from patients with neurodegenerative disease, conducting studies can be efficient (15).

CRISPR-Cas9 and transcription activator-like effector nucleases (TALENs) are efficient tools for gene editing as both methods involve inducing DNA double-strand breaks and recruit cell repair mechanisms for genetic change (16). A difference between the two methods is that CRISPR-Cas9 relies on single-guide (sgRNA) to target specific DNA sequences, while TALENs use DNA-binding domains (DBDs) to target the specific DNA (17). The ability to have higher cleavage efficiency makes CRISPR-Cas9 preferable over TALENs (7).

The two main *ABCA4* gene variants are c.4253+4C>T and c.3211_3212instGT (7). These variants cause a splicing defect and generate a frameshift, respectively (7). Even though there are no current treatments for STGD1, hiPSC studies conducted aim to correct the 2 *ABCA4* gene mutations using CRISPR-Cas9. Therefore, using CRISPR-Cas9 holds significant promise in fixing the mutation of the *ABCA4* gene in STGD1, and offers hope in treating a wide range of inherited eye disorders (7).

Patient-derived fibroblasts from 2 individuals with STGD1, each harboring heterozygous mutations in *ABCA4*, were reprogrammed into human induced pluripotent stem cell (hiPSC) lines (18). The pathogenicity of each variant was determined using the ENSEMBL Variant Effect Predictor (VEP) (7,19). VEP is a computational tool used to determine the impact of a genetic mutation with the use of algorithms (7,19). Single-guide RNA (sgRNAs) and TALENs were designed, with sgRNAs being selected based on efficacy with the least off-target effects

(7). CRISPR-Cas9 was introduced into the hiPSCs by transfecting hiPSCs with ribonucleoprotein (RNP) (7). The RNP consisted of Cas9, sgRNA, and single-strand oligodeoxynucleotides (ssODNs), necessary for gene editing (7). The function of ssODNs is to allow precise gene editing by allowing homology-directed repair (HDR) mediated modification to take place (7,20). PCR amplification was completed on the *ABCA4* gene target region with the new modification made by CRISPR-Cas9 (7). Additionally, Sanger sequencing was carried out to determine whether the correction of the *ABCA4* gene resulted in off-target alterations (7). Lastly, RT-PCR was conducted to determine if the *ABCA4* gene had been corrected and if the cells could differentiate into the 3 germ layers (7).

Upon conducting the *in silico* analysis, the main 2 variants of the *ABCA4* mutations were all missense mutations except c.514G>A, which are pathogenic (7). Additionally, c.3211_3212inGT and c.2023G>A are the main gene variant causing STGD1 since these variants appear at a low frequency in the population. The cleavage efficiency for sgRNA/Cas9 was between 15% and 45%, which was higher than that of the DNA cleavage performed by TALENs. Due to the low cutting made by TALENs, CRISPR-Cas9 was used to correct the STGD1 mutations in the *ABCA4* gene.

The use of ssODNs plays a critical role in CRISPR-Cas9 gene editing by serving as repair templates during homology-directed repair (HDR) following cleavage by the Cas9 RNP complex (7). ssODNs are precise in carrying out HDR-mediated repairs, and ssODNs repair single-nucleotide substitutions (21). HDR-mediated modifications are much more precise than non-homologous end joining (NHEJ) because NHEJ is more error-prone and more likely to generate indels when the two ends of the double-stranded breaks are re-ligated (7).

The gene-edited hiPSC clones were checked to see whether differentiation occurred to form the 3 germ layers. RT-PCR and immunofluorescence indicated that the gene-edited cells can divide into the three germ layers. Thus, indicating that pluripotency is conserved (7).

Two sgRNAs had off-target effects, sgRNA2 had 7, and sgRNA6 had 57 off-targets. After conducting Sanger sequencing, it was confirmed that the editing targeted the correct location of interest and did not cause any other genomic alterations (7).

Even though there have been no therapies to cure visual loss in STGD1 patients as of yet, there have been studies to analyze the effects of CRISPR-Cas9-mediated gene editing (22). However, there are issues with an *in vivo* CRISPR-Cas9 system such as off-target mutations and double stranded break related oncogenesis (22). The review reported that two sgRNAs had off-target effects, and even though they did not cause any genomic issues, gene editing still caused off-target effects (22).

Additionally, hiPSCs offer a robust *in vitro* model for investigating neurodegenerative diseases such as STGD1, where primary neural tissues are inaccessible for direct study (15). RNP complexes comprising Cas9, sgRNA, and ssODNs facilitated precise gene editing via homology-directed repair, while the presence of the ssODN also reduced Cas9 re-cutting at successfully edited loci (21,22). In addition, delivering Cas9 via the RNP complex is more efficient for single-base substitution in comparison to plasmid-based Cas9 transfection (20).

The use of ssODN-gene editing results in the *ABCA4* gene being edited without causing genomic alterations, thus indicating that CRISPR-Cas9 can be potentially used for the treatment of STGD1 (7). hiPSC-based studies using CRISPR-Cas9 have advanced gene editing research; however, its *in vivo* application remains nascent, with further investigation needed to assess long-term efficacy and potential adverse effects in treating STGD1 (7).

Retinitis Pigmentosa

Retinitis pigmentosa (RP) is an inherited disorder where damage to the photoreceptors, rods and cones in the eye, result in progressive visual loss. RP is a progressive, long-lasting retinal disorder that typically worsens over time and is classified as either syndromic or non-syndromic, depending on the presence of associated systemic features. Syndromic RP can affect other organs in the body whereas non-syndromic affects the eye only. Most of the RP cases are non-syndromic, and about 20% to 30% are syndromic (24). In RP, the most common genes mutated are the ones involved in the visual cascade (34). The visual cascade involves the photochemical reaction where light is converted to an electrical signal in the retina (35).

RP has several clinical manifestations, including night blindness, dust-like particles collecting in the

vitreous, posterior cataracts, and fundus damage. Night blindness is one of the symptoms that first occurs because the rods are damaged and cannot properly adjust to dim lighting. Early diagnosis can be detected with dust-like particles in the vitreous. The severity of the posterior cataracts associated with RP corresponds to the age of those who are affected. Lastly, the appearance of the fundus in RP also helps determine the stage of the disease when no other symptoms occur (25). The fundus of the eye is essential to vision because it is composed of the retina, macula, optic, disc, fovea, and blood vessels (36).

The prevalence of RP is estimated at 1 in 3,000 to 1 in 7,000 individuals (24). Approximately 181 genes have been mapped to chromosomal loci associated with inherited RP, and around 129 genes have been identified at the sequence level, underscoring the disorders extensive genetic heterogeneity (26). A specific mutation that will be discussed in more detail involves the retinitis pigmentosa GTPase regulator (RPGR) which is associated with X-linked retinitis pigmentosa (XLRP) - a form that accounts for 10%-20% of all RP cases and is among the most severe (27).

Currently, only 1 approved treatment exists for a sub-population of patients experiencing RP (31). Other treatments that aim to help manage the condition include gene therapy, vitamin therapy to protect photoreceptors, and retinal transplants for more severe cases (32). Gene editing therapy has been used as a primary way to study the genetic characteristics of many diseases including RP. Gene editing for the retina is ideal because it is easily accessible and is also isolated by the blood retinal barrier (28). CRISPR-Cas9 has shown promising treatments for RP and many other diseases (23).

Recent animal studies have shown how specific gene therapies in rats can lead to promising treatments in humans for RP. The purpose of the investigation was to test the efficacy of short palindromic repeat/Cas9-mediated gene editing therapy in rodents with RPGR. Mice with *Rpgr*^{-/-}/*Cas9*^{+/+}/WT genotype received subretinal injections of adenovirus vectors with the sgRNA and donor template, and their therapeutic effects were examined at 1, 6, and 12 months. The *Rpgr*^{-/-}/*Cas9*^{+/+}/WT genotype consists of the hemizygous knockout mutation in the *Rpgr* gene with one allele of the *Cas9* gene with the other allele being wild type. A 6-month-old mouse is equivalent

to a human in their 30s, a 12-month-old mouse is equivalent to a human in their mid-40s and an 18-month-old mouse is equivalent to an old human.

A total of 72 mice were used in the study where mRNA of in vitro-transcribed Cas9 and sgRNA were injected into the zygotes of the mice that were authenticated with PCR and sequencing. After receiving the injection, the mice were given 1% atropine drops and neomycin-polymyxin B-dexamethasone ophthalmic ointments. Atropine drops are a type of medication used to dilate the pupils (28). In order to determine the effects of the injection, histology and immunofluorescence, fundus photography, and DNA analyses were conducted. The immunofluorescence technique allows for the detection of antigens in different tissues (30). In this case the immunofluorescence allows for the detections of RPGR re-expression in the retina.

Close examination of the control and RPGR mice revealed that photoreceptors of the mice with engineered RPGR indeed showed slow retinal degeneration. Retinal fundus imaging revealed that small yellow-white spots appeared within the first 3 months, becoming sparse by 12 months, although pigment deposition persisted. Histological evaluation of retinal sections from WT and RPGR mice showed that in RPGR mice, subtle age-related photoreceptor cell loss was evident by 3 months, progressed by 6 months, and became more pronounced by 12 months. The retinal morphology of mice treated with mutant RPGR with 2 different vectors showed that there was extensive and great retinal photoreceptor preservation. Nine layers of the retina had preserved photoreceptors while the untreated portion of the retina only had 5. The outer nuclear layer of the treated areas was also thicker than those that were not treated (29).

Other gene editing therapies have been tested on RP mutants, however, CRISPR-Cas9 has been shown to be a promising therapy. Some other gene therapies that help treat a certain disease add a functional or partially functional copy of a gene without removing the mutant (or dysfunctional) gene. In contrast, CRISPR-Cas9 can generate specific modifications to a locus and eliminate any defective DNA. The results from the above study show that the CRISPR-Cas9 mediated RPGR gene therapy prevented any photoreceptor degeneration and that the treatment was able to persist for longer periods of time. The study performed

on rats showed promising results in translation to CRISPR-Cas9 in humans.

Leber's Congenital Amaurosis

Leber's congenital amaurosis (LCA) is one of the most severe retinal dystrophies associated with childhood blindness (37). LCA is a rare inherited eye disorder prevalent in 1/30,000 people and 1/81,000 newborn babies worldwide (38). Although rare, it is one of the most common inherited retinal diseases (IRDs) with a prevalence of greater than 5% (38). The disease causes severe vision loss and degeneration in the photoreceptor cells, specifically the rods and cones, in the retina (39).

LCA is associated with mutations in approximately 38 different genes (40). One of the most common mutations causing the disease is in the *CEP290* gene (40). There are 18 known types of LCA, each caused by a different gene mutation (41). The *CEP290* mutation causes LCA10 which is responsible for more than 30% of all cases of LCA globally (42). In the United States, this mutation is responsible for 77% of cases (43). The *CEP290* mutation results from a switch in a base sequence from adenine to guanine in intron 26 on chromosome 12 (43). This mutation generates an aberrant splice site, leading to the integration of a cryptic exon into the DNA sequence, resulting in a truncated *CEP290* protein which leads to the symptomology associated with LCA10 (43).

Currently, there are no known cures for this mutation, but multiple clinical trials are underway to evaluate possible curative treatments (41). The most impactful clinical trial that has been published is the BRILLIANCE trial (44). This study specifically looked at treating the *CEP290* mutation with a CRISPR-Cas9 sequence to regenerate the loss of photoreceptor cells in the retina. This trial was the first human-based CRISPR-Cas9 ocular disease model and used EDIT-101, a specific CRISPR-Cas9, that contained an adeno-associated virus 5(AAV5), *Staphylococcus aureus* Cas9 nuclease, G coupled protein kinase 1, and guide RNAs (44). These factors are required for any CRISPR Cas9 model to help localize the cut in the DNA sequence for the specific mutations (45, 46).

The above study had 14 participants, 2 of which were children age 9 and 14 (44). The participants were either homozygous or heterozygous in their inheritance of LCA10. The study's main goals were the safety of the treatment and to look at the efficacy

of the gene therapy in treating LCA. The efficacy was analyzed using tests examining four main outcomes: visual acuity, retinal sensitivity, visual-related functional navigation, and vision-related quality of life. All of these factors are impacted by patients with the CEP290 mutation that results in LCA.

The changes in participants' baseline visual acuity were looked at using the Early Treatment Diabetic Retinopathy Study (ETDRS) and the Berkley Rudimentary Vision Test (BRVT) (44). The ETDRS is a chart that contains multiple rows of equally spaced 5-letter groupings that get increasingly smaller as you move downward (47). The participants who were determined to have reduced visual acuity based on the ETDRS chart used the BRVT to find their visual acuity. The BRVT is a simple and effective test used to look at visual acuity in individuals determined to have significantly reduced visual acuity (48). Retina sensitivity to red, blue, and white light was measured with a full field stimulus test (FST). Visual-related functional navigation was measured using the Ora-Visual Navigation Challenge (VNC), a mobility test requiring participants to navigate obstacles under different light conditions (49). Finally, the participant's vision-related quality of life was measured in children using the Children's Visual Function Questionnaire (CVFQ) and in adults using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) (44).

EDIT-101 was administered as a single-dose subretinal injection after participants underwent a pars plana vitrectomy and 3 days of oral prednisone. The purpose of the pars plana vitrectomy is to remove some part of the vitreous humor in the eye to allow easier access to the posterior part of the eyeball for the subretinal injection (50). The EDIT-101 was given in either a low dose for cohort 1, an intermediate dose for cohort 2, or a high dose for cohort 3; cohort 4 consisted of the 2 child participants who received the intermediate dose. After the EDIT-101 injection, oral prednisone was continued for 3 weeks in all cohorts.

After 2 years of monitoring the participants for varying amounts of time, the results showed significant improvements due to the insertion of the EDIT-101 CRISPR-Cas9 treatment (44). The treatment was safe, with 22 adverse side effects reported. Most of these side effects were predicted and expected. The treatment was also effective, with 11 out of the 14 participants finding support in at least 1 of the 4 main

efficacy outcomes of visual acuity, retinal sensitivity, visual-related functional navigation, and vision-related quality of life. Six out of the 14 participants found improvement in 2 or more efficacy outcomes.

This study supports future research involving CRISPR-Cas9 as a potential curative treatment for the genetic mutation of CEP290. Most participants showed efficacy of inserting EDIT-101, a CRISPR-Cas9 gene therapy, with minimal adverse effects. It also shows support for conducting more research on other mutations responsible for LCA, such as *CRB1*, *GUCY2D*, and *RPE65* (51). The BRILLIANCE clinical trial opens the door for future human studies to be done, as the trial showed gene editing as a possible treatment for mutations that cause other IRDs like LCA.

Overall, the BRILLIANCE clinical trial was a pivotal study in showing genetic therapies' impact on human inherited diseases. Further study in CRISPR-Cas9 models may show the potential to generate treatments for diseases caused by mutations with previously unknown cures.

Conclusion

CRISPR-Cas9, a powerful gene-editing tool, has seen remarkable advancements over the past decade (6). This review focuses on its application in 3 inherited eye disorders- Stargardt's disease (STGD1), retinitis pigmentosa (RP), and Leber's congenital amaurosis (LCA)- to evaluate the therapeutic potential of CRISPR-Cas9 as a form of gene therapy.

The study with STGD1 showed promising gene editing in hiPSCs and CRISPR-Cas9 (7). However, further studies need to be conducted to do *in vivo* gene editing with CRISPR-Cas9. The study with RP in mice indicated that CRISPR-Cas9 mediated with *RPGR* gene therapy prevents photoreceptor degeneration. However, further studies need to be conducted to see the effects of CRISPR-Cas9 on humans (27). The study with EDIT-101 and its efficacy with the CEP290 mutation was effective in the human participants with LCA10 and showed promise for further *in vivo* studies on humans to correct inherited genetic mutations (44). The findings in these studies demonstrate the effects of CRISPR-Cas9 on STGD1, RP, and LCA and provide strong support for future research into genetic therapy as a possible curative treatment for eye diseases caused by mutations in the human genome.

Disclosures

The authors have no conflicts of interest or financial disclosures relevant to this manuscript.

Acknowledgments

None.

References

1. Graw J. Eye development. *Curr Top Dev Biol*. 2010; 90:343-86.
2. Zhou C, Li S, Ye L, Chen C, Liu S, Yang H, et al. Visual impairment and blindness caused by retinal diseases: A nationwide register-based study. *J Glob Health*. 2023; 13:04126.
3. Henderson RH. Inherited retinal dystrophies. *Paediatr Child Health*. 2020; 30(1):19-27.
4. Redman M, King A, Watson C, King D. What is CRISPR/Cas9? *Arch Dis Child Educ Pract Ed*. 2016; 101(4):213-5.
5. Vasiliou SK, Diamandis EP, Church GM, Greely HT, Baylis F, Thompson C, et al. CRISPR-Cas9 system: Opportunities and concerns. *Clin Chem*. 2016; 62(10):1304-11.
6. Khalil AM. The genome editing revolution: Review. *J Genet Eng Biotechnol*. 2020; 18(1):68.
7. Siles L, Martinez-Garcia M, Palfi A, Alifragis P, Irion S, Warre-Cornish K, et al. Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients. *Mol Ther Nucleic Acids*. 2023; 32:64-79.
8. Lambertus S, van Huet RA, Bax NM, Hoefsloot LH, Cremers FP, Boon CJ, et al. Early-onset Stargardt disease: Phenotypic and genotypic characteristics. *Ophthalmol*. 2015; 122(2):335-44.
9. Westeneng-van Haaften SC, Boon CJ, Cremers FP, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt's disease. *Ophthalmol*. 2012; 119(6):1199-210.
10. Tsang SH, Sharma T. Stargardt disease. *Adv Exp Med Biol*. 2018; 1085:139-51.
11. Koenekoop RK. The gene for Stargardt disease, ABCA4, is a major retinal gene: A mini-review. *Ophthalmic Genet*. 2003; 24(2):75-80.
12. Sun H, Nathans J. Mechanistic studies of ABCR, the ABC transporter in photoreceptor outer segments responsible for autosomal recessive Stargardt disease. *J Bioenerg Biomembr*. 2001; 33(6):523-30.
13. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: Clinical features, molecular genetics, animal models and therapeutic options. *Br J Ophthalmol*. 2017; 101(1):25-30.
14. Poliwoda S, Noor N, Downs E, Schaaf A, Cantwell A, Ganti L, et al. Stem cells: A comprehensive review of origins and emerging clinical roles in medical practice. *Orthop Rev (Pavia)*. 2022; 14(3):37498.
15. Rivetti di Val Cervo P, Besusso D, Conforti P, Cattaneo E. hiPSCs for predictive modelling of neurodegenerative diseases: Dreaming the possible. *Nat Rev Neurol*. 2021; 17(6):381-92.
16. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends Biotechnol*. 2013; 31(7):397-405.
17. Boettcher M, McManus MT. Choosing the right tool for the job: RNAi, TALEN, or CRISPR. *Mol Cell*. 2015; 58(4):575-85.
18. Riera M, Patel A, Burés-Jelstrup A, Corcostegui B, Chang S, Pomares E, et al. Generation of two iPS cell lines (FRIMO003-A and FRIMO004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations. *Stem Cell Res*. 2019; 36:101389.
19. Fawzy M, Marsh JA. Understanding the heterogeneous performance of variant effect predictors across human protein-coding genes. *Sci Rep*. 2024; 14(1):26114.
20. Okamoto S, Amaishi Y, Maki I, Enoki T, Mineno J. Highly efficient genome editing for single-base substitutions using optimized ssODNs with Cas9-RNPs. *Sci Rep*. 2019; 9(1):4811.
21. Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat Biotechnol*. 2016; 34(3):339-44.

22. Hu X, Zhang B, Li X, Li M, Wang Y, Dan H, et al. The application and progression of CRISPR/Cas9 technology in ophthalmological diseases. *Eye (Lond)*. 2023; 37(4):607-17.
23. Liu W, Liu S, Li P, Yao K. Retinitis pigmentosa: Progress in molecular pathology and biotherapeutical strategies. *Int J Mol Sci*. 2022; 23(9):4883
24. Verbakel SK, Van Huet RAC, Boon CJF, Den Hollander AI, Collin RWJ, Klaver CCW, et al. Non-syndromic retinitis pigmentosa. *Prog Retin Eye Res*. 2018; 66:157
25. Fahim AT, Daiger SP, Weleber RG, Adam MP, Feldman J, Mirzaa G. Nonsyndromic retinitis pigmentosa overview. *GeneReviews[Internet]*. 2023
26. Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. *Arch Ophthalmol*. 2007; 125(2):151-8
27. Hu S, Du J, Chen N, Jia R, Zhang J, Liu X, et al. In vivo CRISPR/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa. *Invest Ophthalmol Sci*. 2020; 9;61(4):31
28. Cleveland Clinic. Atropine eye solution.[Internet]. Cleveland, OH: Cleveland Clinic; 2024[cited 2024 Nov 17]. Available from <https://my.clevelandclinic.org/health/drugs/20729-atropine-eye-solution>
29. Mayo Clinic. Neomycin, polymyxin b, and dexamethasone (ophthalmic route). [Internet]. Rochester, MN: Mayo Clinic; 2024[cited 2024 Nov 17]. Available from <https://www.mayoclinic.org/drugs-supplements/neomycin-polymyxin-b-and-dexamethasone-ophthalmic-route/description/drg-20406312#>
30. Im K, Mareninov S, Diaz MFP, Yong WH. An introduction to performing immunofluorescence staining. *Methods Mol Biol*. 2019;1897:299-311
31. Cross N, Steen CC, Zegaoui Y, Satherley A, Angelillo L. Current and future treatment of retinitis pigmentosa. *Clin Ophthalmol*. 2020; 16:2909-2921
32. Musarella MA, Macdonald IM. Current concepts in the treatment of retinitis pigmentosa. *J Ophthalmol*. 2011;2011:753547
33. Hamel C. Retinitis pigmentosa. *Orphanet J Rare Dis*. 2006;1:40
34. Phelan JK, Bok D. A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. *Mol Vis*. 2000; 8:6:116-24
35. Nguyen QD, Rodrigues EB, Farah ME, Mieler WF. Retinal pharmacotherapy. 1st ed. Amsterdam; Elsevier; 15 p.
36. AAO. American Academy Of Ophthalmology [Internet]. Sanfrancisco, CA : AAO; 2020[cited 2024 Nov 17]. Available from <https://www.aao.org/eye-health/anatomy/fundus#:~:text=The%20fundus%20is%20the%20inside,find%2C%20watch%20and%20treat%20disease>.
37. Russell SR, Drack AV, Cideciyan AV, Jacobson SG, Leroy BP, Van Cauwenbergh C, et al. Intravitreal antisense oligonucleotide sepirofen in Leber congenital amaurosis type 10: A phase 1b/2 trial. *Nat Med*. 2022; 28(5):1014–1021.
38. Chiu W, Lin TY, Chang YC, Isahwan-Ahmad Mulyadi Lai H, Lin SC, Ma C, et al. An update on gene therapy for inherited retinal dystrophy: Experience in Leber congenital amaurosis clinical trials. *Int J Mol Sci*. 2021; 22(9):4534.
39. Coussa RG, Lopez Solache I, Koenekoop RK. Leber congenital amaurosis, from darkness to light: An ode to Irene Maumenee. *Ophthalmic Genet*. 2017; 38(1):7-15.
40. Huang CH, Yang CM, Yang CH, Hou YC, Chen TC. Leber's congenital amaurosis: Current concepts of genotype-phenotype correlations. *Genes (Basel)*. 2021; 12(8):1261.
41. University of Arizona. Leber Congenital Amaurosis. [Internet]. Arizona: University of Arizona; [cited 2024 Nov 21]. Available from: <https://disorders.eyes.arizona.edu/disorders/Leber-congenital-amaurosis>
42. Biasutto P, Dulla K, Adamson P, Schulkens I, Schmidt I, Lane A, et al. QR-110 treatment for Leber's congenital amaurosis type 10: Restoration of CEP290 mRNA levels and ciliation in LCA10 iPSC-derived optic cups. *Invest Ophthalmol Vis Sci*. 2017; 58(8):249.
43. Daich Varela M, Cabral de Guimaraes TA, Georgiou M, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: Current management and clinical trials. *Br J Ophthalmol*. 2022;106(4):445-451.

44. Pierce EA, Aleman TS, Jayasundera KT, Ashimatey BS, Kim K, Rashid A, et al. Gene editing for CEP290-associated retinal degeneration. *N Engl J Med*. 2024; 390(21):1972–1984.
45. Denes CE, Cole AJ, Aksoy YA, Li G, Neely GG, Hesselson D. Approaches to enhance precise CRISPR/Cas9-mediated genome editing. *Int J Mol Sci*. 2021; 22(16):8571.
46. Ruan GX, Barry E, Yu D, Lukason M, Cheng SH, Scaria A. CRISPR/Cas9-mediated genome editing as a therapeutic approach for Leber congenital amaurosis 10. *Mol Ther*. 2017; 25(2):331-341.
47. Bailey IL, Lovie-Kitchin JE. Visual acuity testing. From the laboratory to the clinic. *Vision Res*. 2013; 90: 2–9.
48. Bailey IL, Jackson AJ, Minto H, Greer RB, Chu, MA. The Berkeley rudimentary vision test. *Optom Vis Sci*. 2012; 89(9):1257–1264.
49. Shapiro A, Corcoran P, Sundstrom C, Angjeli E, Rodriguez JD, Abelson MB, et al. Development and validation of a portable visual navigation challenge for assessment of retinal disease in multi-centered clinical trials. *Invest Ophthalmol Vis Sci*. 2017; 58(8):3290.
50. Iovino C, Rosolia A, Damiano L, Iodice CM, Di Iorio V, Testa F, et al. Pars plana vitrectomy in inherited retinal diseases: A comprehensive review of the literature. *Life (Basel)*. 2023; 13(6):1241.
51. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: Genes, proteins and disease mechanisms. *Prog Retin Eye Res*. 2008; 27(4):391–419.